Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
2.560
-0.280 (-9.86%)
At close: Nov 4, 2024, 4:00 PM
2.550
-0.010 (-0.39%)
After-hours: Nov 4, 2024, 7:23 PM EST

Company Description

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.

Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021.

The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Fractyl Health, Inc.
Fractyl Health logo
Country United States
Founded 2010
IPO Date Feb 2, 2024
Industry Biotechnology
Sector Healthcare
Employees 102
CEO Harith Rajagopalan

Contact Details

Address:
3 Van de Graaff Drive, Suite 200
Burlington, Massachusetts 01803
United States
Phone 781-902-8800
Website fractyl.com

Stock Details

Ticker Symbol GUTS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001572616
ISIN Number US35168W1036
Employer ID 27-3553477
SIC Code 3841

Key Executives

Name Position
Dr. Harith Rajagopalan M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Jay D. Caplan BSEE, MBA Co-Founder, Chief Product Officer and President
Dr. Timothy J. Kieffer Ph.D. Chief Scientific Officer
Lisa A. Davidson MBA Chief Financial Officer and Treasurer
Sarah S. Toomey Esq. General Counsel and Corporate Secretary
Adrian Kimber Chief Commercial Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 8-K Current Report
Sep 12, 2024 144 Filing
Aug 14, 2024 8-K Current Report
Aug 14, 2024 10-Q Quarterly Report
Jul 30, 2024 8-K Current Report
Jun 24, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
May 13, 2024 8-K Current Report
Apr 1, 2024 10-K Annual Report
Apr 1, 2024 8-K Current Report